Evidence map›Paper›PMID 36782197›Full record

ArticleJournal of translational medicine2023

LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets.

Rong Guo, Yonghui Su, Qi Zhang, Bingqiu Xiu, Sheng Huang, Weiru Chi, Liyi Zhang, Lun Li, Jianjing Hou, Jia Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. The role of LncRNA-mediated autophagy in cancer progression.Frontiers in cell and developmental biology · 2024
    Review
  4. Review
  5. Long Non-Coding RNAs as "MYC Facilitators".Pathophysiology : the official journal of the International Society for Pathophysiology · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Rong Guo *Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Yonghui Su *Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Qi Zhang *Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Bingqiu XiuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Sheng HuangDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Weiru ChiDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Liyi ZhangDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Lun LiDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Jianjing HouDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Jia WangDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Jiajian ChenDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Yayun ChiDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China. yychi@126.com.
Jingyan XueDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China. xuejy@163.com.
Jiong WuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China. wujiong1122@vip.sina.com.ORCID 0000-0002-8103-0505
Shanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetastasis is the predominant cause of mortality in patients with breast cancer. Long noncoding RNAs (lncRNAs) have been shown to drive important phenotypes in tumors, including invasion and metastasis. However, the lncRNAs involved in metastasis and their molecular and cellular mechanisms are still largely unknown.

methodsThe transcriptional and posttranscriptional processing of LINC00478-associated cytoplasmic RNA (LacRNA) was determined by RT-qPCR, semiquantitative PCR and 5'/3' RACE. Paired-guide CRISPR/cas9 and CRISPR/dead-Cas9 systems was used to knock out or activate the expression of LacRNA. Cell migration and invasion assay was performed to confirm the phenotype of LacRNA. Tail vein model and mammary fat pad model were used for in vivo study. The LacRNA-PHB2-cMyc axis were screened and validated by RNA pulldown, mass spectrometry, RNA immunoprecipitation and RNA-seq assays.

resultsHere, we identified a novel cytoplasmic lncRNA, LacRNA (LINC00478-associated cytoplasmic RNA), derived from nucleus-located lncRNA LINC00478. The nascent transcript of LINC00478 full-length (LINC00478_FL) was cleaved and polyadenylated, simultaneously yielding 5' ends stable expressing LacRNA, which is released into the cytoplasm, and long 3' ends of nuclear-retained lncRNA. LINC00478_3'RNA was rapidly degraded. LacRNA significantly inhibited breast cancer invasion and metastasis in vitro and in vivo. Mechanistically, LacRNA physically interacted with the PHB domain of PHB2 through its 61-140-nt region. This specific binding affected the formation of the autophagy degradation complex of PHB2 and LC3, delaying the degradation of the PHB2 protein. Unexpectedly, LacRNA specifically interacted with PHB2, recruited c-Myc and promoted c-Myc ubiquitination and degradation. The negatively regulation of Myc signaling ultimately inhibited breast cancer metastasis. Furthermore, LacRNA and LacRNA-mediated c-Myc signaling downregulation are significantly associated with good clinical outcomes, take advantage of these factors we constructed a prognostic predict model.

conclusionTherefore, our findings propose LacRNA as a potential prognostic biomarker and a new therapeutic strategy.

Indexed as

RNA, Long NoncodingSkin NeoplasmsCell Line, TumorCell ProliferationCutaneous Malignant MelanomaGene Expression Regulation, NeoplasticHumansPrognosisProto-Oncogene Proteins c-mycSignal TransductionProto-Oncogene Proteins c-mycRNA, Long NoncodingBreast cancerc-MycLacRNAMetastasisPHB2

Identifiers

PMID36782197
PMCPMC9926633
OpenAlexW4320480705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.